CytomX Therapeutics CTMX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $35.54M-53.4% | $76.2M-32.9% | $113.63M-19.5% | $141.1M-4.4% | $147.56M+6.8% | ||
| $69.1M+0.5% | $68.73M+10.3% | $62.28M-8.9% | $68.35M-14.8% | $80.2M-3.8% | ||
| $31.1M+4.2% | $29.84M+6.2% | $28.1M-5.2% | $29.63M-5.6% | $31.4M+5.6% | ||
| $100.2M+1.7% | $98.57M+9.1% | $90.39M-7.7% | $97.98M-12.2% | $111.6M-1.3% | ||
| $100.2M+1.7% | $98.57M+9.1% | $90.39M-7.7% | $97.98M-12.2% | $111.6M-1.3% | ||
| -$64.66M-189% | -$22.37M-196% | $23.25M-46.1% | $43.13M+19.9% | $35.96M+43.9% | ||
| -181.9%-153pp | -29.4%-49.8pp | 20.5%-10.1pp | 30.6%+6.2pp | 24.4%+6.3pp | ||
| $5.74M+10.3% | $5.21M+4.1% | $5M-2.0% | $5.1M-13.4% | $5.9M-17.4% | ||
| —— | —— | $14K+600% | $2K+112% | -$17K+56.4% | ||
| -$58.91M-244% | -$17.13M-161% | $28.26M-41.4% | $48.23M+15.3% | $41.84M+30.4% | ||
| $234K-1.3% | $237K-3.3% | $245K-1.2% | $248K+5.1% | $236K+5.8% | ||
| -$59.14M-241% | -$17.37M-162% | $28.02M-41.6% | $47.98M+15.3% | $41.6M+30.5% | ||
| -166.4%-144pp | -22.8%-47.4pp | 24.7%-9.3pp | 34%+5.8pp | 28.2%+5.1pp | ||
| -$0.41-925% | -$0.04-110% | $0.41-28.1% | $0.57+16.3% | $0.49+25.6% | ||
| -$0.41-925% | -$0.04-110% | $0.41-28.1% | $0.57+16.3% | $0.49+25.6% | ||
| -$0.41-925% | -$0.04-110% | $0.41-28.1% | $0.57+16.3% | $0.49+25.6% | ||
| 609.3M+17.4% | 519.2M+11.4% | 466M+20.7% | 386.2M+12.9% | 342M+1.3% | ||
| 609.3M+17.4% | 519.1M+11.5% | 465.6M+20.7% | 385.7M+12.9% | 341.5M+1.5% | ||
| -$0.41-925% | -$0.04-110% | $0.41-28.1% | $0.57+16.3% | $0.49+25.6% | ||
| -$0.41-925% | -$0.04-110% | $0.41-28.1% | $0.57+16.3% | $0.49+25.6% | ||
| -$59.04M-242% | -$17.28M-162% | $28.08M-41.5% | $48.02M+15.4% | $41.61M+30.9% | ||
| —— | -$3M-33.3% | -$2.25M-50.0% | -$1.5M-100% | -$750.5K— | ||
| $103K+22.6% | $84K+31.3% | $64K+73.0% | $37K+311% | $9K+113% | ||
| —— | —— | $14K+600% | $2K+112% | -$17K+56.4% | ||
| $35.54M-53.4% | $76.2M-32.9% | $113.63M-19.5% | $141.1M-4.4% | $147.56M+6.8% | ||
| -$64.66M-189% | -$22.37M-196% | $23.25M-46.1% | $43.13M+19.9% | $35.96M+43.9% | ||
| -$64.51M-190% | -$22.22M-195% | $23.39M-45.9% | $43.27M+19.8% | $36.11M+43.6% | ||
| -$64.51M-190% | -$22.22M-195% | $23.39M-45.9% | $43.27M+19.8% | $36.11M+43.6% | ||
| -181.5%-152pp | -29.2%-49.7pp | 20.6%-10.1pp | 30.7%+6.2pp | 24.5%+6.3pp | ||
| -$64.66M-189% | -$22.37M-196% | $23.25M-46.1% | $43.13M+19.9% | $35.96M+43.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is CytomX Therapeutics's revenue?
- CytomX Therapeutics (CTMX) generated $35.5M in revenue over the trailing twelve months, down 75.9% year over year.
- Is CytomX Therapeutics profitable?
- CytomX Therapeutics is not currently profitable: it reported a net loss of $59.1M over the trailing twelve months, a -166.4% net margin.
- What is CytomX Therapeutics's earnings per share?
- CytomX Therapeutics's diluted EPS over the trailing twelve months is $-0.41.
- Where does CytomX Therapeutics's income statement data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
